RESUMO
Background: Novel approaches using virtual computed tomography (CT) guidance, namely electromagnetic navigation transthoracic needle biopsy (EMN-TTNB), enable physicians to perform percutaneous lung biopsies. However, there are very few studies on the clinical experiences of EMN-TTNB, and in previous studies, the procedure was usually performed under deep sedation. This study aimed to determine the diagnostic accuracy and safety of EMN-TTNB under moderate sedation. Methods: We conducted a retrospective analysis of patients who underwent EMN-TTNB under moderate sedation between May 2021 and November 2022 at Hallym University Dongtan Sacred Heart Hospital in South Korea. Moderate sedation was achieved with midazolam injection in the bronchoscopy room using the Veran SPiNperc EM guidance system (Veran Medical, St Louis, MO, USA). Clinical data were collected by review of medical records, and diagnostic accuracy and safety were calculated. Results: Thirty-two patients were enrolled (mean age 70.8±11.1 years); 56.3% were male. The mean size of the pulmonary lesions was 36.9±17.4 mm, and the median (interquartile range) distance from the pleura was 15.5 (0.0-30.0) mm. The diagnostic accuracy of EMN-TTNB was 75.0% (21/28), excluding four indeterminate cases. Fourteen patients (50.0%, 14/28) had true-positive and seven patients (25.0%, 7/28) had true-negative lesions. There were no severe adverse reactions such as pneumothorax, respiratory failure, or death, except one case of hemoptysis. Conclusions: EMN-TTNB under moderate sedation showed an acceptable diagnostic accuracy and good safety profile. The new technology allows physicians to perform percutaneous lung biopsies without the intervention of a radiologist or anesthesiologist.
RESUMO
The clinical outcomes of patients with lung cancer coexisting with chronic kidney disease (CKD) are reported to have been conflicting. There is insufficient evidence for treatment and prognosis of lung cancer according to renal function in patients with CKD. We evaluate clinical course and prognostic factors of lung cancer according to the renal function of moderate CKD patients. A retrospective, multicenter study of lung cancer patients with moderate CKD was performed. Moderate CKD was defined as having an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. CKD was classified as stage 3, stage 4, and stage 5 according to eGFR. The cumulative mortality of lung cancer was calculated by competing risks survival analysis, and the risk factors were evaluated by the Cox-proportional hazards model. Among the lung cancer patients with moderate CKD (n = 181), median overall survival (OS) was 11.1 (4.2−31.3) months for stage 3 CKD patients, 6.0 (1.8−16.3) months for stage 4 CKD patients, and 4.7 (2.1−40.1) months for stage 5 CKD patients (p = 0.060), respectively. In a subgroup analysis, CKD stage was associated with an increased mortality in early-stage non-small cell lung cancer (NSCLC). Cox regression analysis revealed that age ≥ 75 years (adjusted hazard ratio (aHR), 1.581; 95% confidence interval (CI), 1.082−2.310), Charlson comorbidity index (aHR, 1.669; 95% CI, 10.69−2.605), and stage IV NSCLC (aHR, 2.395; 95% CI, 1.512−3.796) were associated with increased mortality risk, whereas adenocarcinoma (aHR, 0.580; 95% CI, 0.352−0.956) and stage 3 CKD (aHR, 0.598; 95% CI, 0.399−0.895) were associated with decreased mortality risk. In conclusion, the mortality risk of patients with lung cancer was lower in stage 3 CKD compared with stage 4 or 5 CKD. In addition, in the early stages of NSCLC, the CKD stage affected the prognosis, but not in the advanced stage NSCLC.